摘要
目的:观察伊曲康唑注射液防治血液系统恶性肿瘤患者伴发真菌感染的临床疗效和安全性。方法:选择我院53例住院血液系统恶性肿瘤患者,符合经验性治疗、拟诊或确诊病例标准。对于确诊或拟诊病例伊曲康唑续贯治疗,剂量为:每次200mg,q12h×2d,之后改为每次伊曲康唑200mg,qd,完成疗程7d以上评价疗效。经验性治疗伊曲康唑静脉给药。经验性治疗以患者体温正常为有效,拟诊或确诊为患者临床表现消失为有效。结果:疗效评估,经验性治疗31例,有效25例(80.65%);确诊9例,有效6例(66.67%);拟诊13例,有效10例(76.92%)。副反应中肝功能异常发生率5.66%,无肾功能损害发生。结论:伊曲康唑注射液在防治血液系统恶性肿瘤继发真菌感染中为高效药物,且药物安全性良好,但在使用时尚需监测肝功能。
Objective：To evaluate the efficacy and safety of itraconazole in the treatment of fungal infection in the patients with hematological malignancies. Method： 53 patients with malignant hematologic diseases were divided into three groups： empirical treatment group, suspected fungal infection group and established group.hraconazole was given in a dose of 200mg twice daily in the first and the second days, from the third day in a dose of 200mg once daily. Response was established as normalization of temperature in the patients receiving itraconazole, and disappearance of clinical signs in the patients with suspected or established infection. Result： The 31 patients were eligible for efficacy evaluation for empirical treatment,and 25 responded to itraeonazole （80.65%）;of 9 established patients,6 responded to itraconazole （66.67%）;of 13 suspected infection patients, 10 responded to itraconazole （76.92%）. As to the side effects, there were no rigor and fever, but hepatotoxiciy were present in 5.66%, and no nephrotoxicity. Conclusion： Itraconazole is a highly effective drug with low side effects in treatment of fungal infections. But the hepatic and renal function tests must be carried out regularly when itraconazole infection is used.
出处
《重庆医科大学学报》
CAS
CSCD
北大核心
2009年第6期786-788,共3页
Journal of Chongqing Medical University
